LONDON--(BUSINESS WIRE)--

Despite the fact that China lags behind in terms of the overall level of genetic engineering drugs, the industry has accumulated rich R&D and industrialization experience as well as capital reserves. Thus, with a host of genetic engineering drug patents to become due, Chinese enterprises, such as Walvax, are committed to the industrialization research of monoclonal antibody, long-acting recombinant protein drugs and other generic drugs with high technical barriers. In April this year, Walvax announced to invest in Shanghai Fengmao to develop and produce genetic engineering generic drugs such as rituximab, bevacizumab, adalimumab, panitumumab, denosumab and long-acting EPO.

New market report China Genetic Engineering Drug Industry Report, 2011-2012 worked out by ResearchInChina delves into a comprehensive discussion of the genetic engineering drug industry from a global perspective and focuses on an insightful review of the sector in China.

Key Topics Covered:

Companies profiled in the report include: Shanghai Lansheng Guojian Pharmaceutical Co., Ltd; Biotech Pharmaceutical Co., Ltd; Anhui Anke Biotechnology (Group) Co., Ltd; GeneScience Pharmaceuticals Co., Ltd; Beijing SL Pharmaceutical Co., Ltd; Jiangsu Sihuan Bioengineering Co., Ltd; Shenzhen Neptunus Interlong Bio-Technique Co., Ltd; 3SBio Inc.; and Tonghua Dongbao Pharmaceutical Co., Ltd.

Report Details:

Title: China Genetic Engineering Drug Industry Report, 2011-2012

Published: July, 2012

Pages: 80

Price: US$ 1,900.00

Read this article:
Genetic Engineering Drug Sector Globally & in China Examined in New Report Published at MarketPublishers.com